Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 14/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 2/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SI | P14410 | 1/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4442988 | 0.91 | PIK3CD (0.63) | PIK3CDATMDRD4DRD3L3MBTL1 | |
| SCHEMBL4184546 | 0.89 | PIK3CD (0.55) | PIK3CDATMDRD4DRD3L3MBTL1 | |
| SCHEMBL4178087 | 0.89 | DPP4 (0.51) | PIK3CDDPP4 | |
| SCHEMBL1597713 | 0.88 | PIK3CD (0.65) | PIK3CDATMDRD4DRD3L3MBTL1 | |
| SCHEMBL1598041 | 0.86 | PIK3CD (0.64) | PIK3CDATMDRD4DRD3L3MBTL1 | |
| SCHEMBL1886097 | 0.86 | PIK3CD (0.64) | PIK3CDATMDRD4DRD3L3MBTL1 | |
| SCHEMBL1598365 | 0.84 | ATM (0.48) | PIK3CDATMMGAMGAASI | |
| SCHEMBL4169507 | 0.81 | PIK3CD (0.60) | PIK3CDATMDPP4 | |
| SCHEMBL2438488 | 0.79 | PIK3CD (0.56) | PIK3CD | |
| SCHEMBL789098 | 0.78 | PIK3CD (0.90) | PIK3CDATMDRD4DRD3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2139882-B1 | 3- SUBSTITUTED QUINOLINE OR QUINOXALINE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS | AMGEN INC (US) | 2013-12-25 | — | — | EP | disclosed |
| US-8329910-B2 | Quinolines for the treatment of PI3K-δ mediated diseases | AMGEN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329910-B2 | Quinolines for the treatment of PI3K-δ mediated diseases | AMGEN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329910-B2 | Quinolines for the treatment of PI3K-δ mediated diseases | AMGEN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8183259-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183258-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183258-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183259-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183259-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183258-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100179177-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-7705018-B2 | Substituted quinolines and their uses in treatment of inflammatory and related conditions | AMGEN INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705018-B2 | Substituted quinolines and their uses in treatment of inflammatory and related conditions | AMGEN INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705018-B2 | Substituted quinolines and their uses in treatment of inflammatory and related conditions | AMGEN INC. (US) | 2010-04-27 | — | — | US | disclosed |
| EP-2139882-A1 | 3- SUBSTITUTED QUINOLINE OR QUINOXALINE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE ( PI3K) INHIBITORS | Amgen Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| US-20090023761-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-01-22 | — | — | US | disclosed |
| US-20090023761-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-01-22 | — | — | US | disclosed |
| US-20090023761-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-01-22 | — | — | US | disclosed |
| WO-2008118455-A1 | δ3- SUBSTITUTED QUINOLINE OR QUINOXALINE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE ( PI3K) INHIBITORS | AMGEN INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008118455-A1 | δ3- SUBSTITUTED QUINOLINE OR QUINOXALINE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE ( PI3K) INHIBITORS | AMGEN INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023761-A1 | Heterocyclic compounds and their uses | MCL1, BCL9, MALT1 | PIK3CD 16/4885ATM 750/4885DPP4 4588/4885 |
| US-20100179177-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PIK3CD 16/4885ATM 750/4885DPP4 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.